ent signaling pathways. . 1 The abbreviations used are: ICAM-1, intercellular adhesion mole-cule-1; PTP, protein tyrosine phosphatases; bpV, bis-peroxovanadium; bpV[pic], bis-peroxovanadium compound carrying the picolinic acid as an auxillary ligand; pI␥RE, palindromic interferon-␥-responsive element; STAT, signal transducers and activators of transcription; PMA, phorbol 12-myristate 13-acetate; Iono, ionomycin; FBS, fetal bovine serum; PBMCs, peripheral blood mononuclear cells; PBS, phosphatebuffered saline; WT, wild type; dsDNA, double-stranded DNA; mut, mutant; IL, interleukin; IFN, interferon; TNF-␣, tumor necrosis factor-␣; bp, base pair.
Intercellular adhesion molecule-1 (ICAM-1) 1 is an inducible cell surface glycoprotein belonging to the immunoglobulin supergene family that shows a molecular mass ranging from 76 to 114 kDa depending on the degree of glycosylation. Its cognate ligands include the membrane-bound integrin receptor LFA-1, Mac-1 on leukocytes, the soluble molecule fibrinogen, rhinoviruses, and Plasmodium falciparum malaria-infected erythrocytes (1) (2) (3) (4) (5) . Within the immune system, ICAM-1 is expressed on cells of the monocyte-macrophage lineage, B lymphocytes, plasma cells, and on both memory and activated T lymphocytes. The association between ICAM-1 and the activated form of the LFA-1 counter-receptor has many important roles in adhesion phenomena involved in the immune system. Its basic function is the induction of a specific and reversible cell-cell adhesion that enables intercellular communication, T cell-mediated defense mechanism, and inflammatory response. In addition, ICAM-1 is also involved in leukocyte-endothelial cell interaction, cell differentiation, and in many pathological complications such as acquired immunodeficiency syndrome, malignancies of both myeloid and lymphoid origin, and allergic asthma (6 -8) .
In a normal immune response, the initial contact between T lymphocytes and antigen presenting cells is made possible through an interaction between adhesion molecules such as ICAM-1 and LFA-1 expressed on the surface of both T lymphocytes and antigen presenting cells. This interaction leads to the association between the T cell receptor-CD3 complex and antigenic peptides in the context of major histocompatibility complex class I and II molecules. If the latter interaction occurs, T cell receptor-CD3 receptors and major histocompatibility complex molecules transmit activation signals in both cell partners. One of the first reactions following such activation is an increase of adhesion strength stabilizing the association between T cells and antigen presenting cells. Additional links occur between other molecules expressed on both cell surfaces that are required for completing adhesion and cell signaling and consequently determining the following response. It ensues that a dysfunction in ICAM-1 gene expression results in an immunological impairment or a physiopathological situation (7, 8) .
The regulation of ICAM-1 gene expression occurs primarily at the level of transcription and is cell type-specific. This phenomenon involves different signaling pathways and several enhancer elements such as palindromic interferon-␥-responsive element (pI␥RE), NF-B, Ets, C/EBP, AP-1-like, Sp1, and retinoic acid response elements (7) (8) (9) . These numerous enhancer elements contained in the ICAM-1 promoter suggest a complex regulation that is still ill-defined in human T cells. In various cell types, signal transducers and activators of transcription (STAT) factors, and more specifically STAT-1 and STAT-3, can bind the ICAM-1 promoter pI␥RE and are strongly involved in ICAM-1 gene expression (10 -19) . NF-B has also been reported to play a pivotal role in ICAM-1 gene regulation where RelA (p65)/RelA, RelA/c-Rel, and RelA/NF-B1 (p50) dimers can potently induce ICAM-1 expression in several cell types (20 -25) . Both JAK/STAT and NF-B pathways have been shown to be modulated by phosphorylation events that lead to their translocation into the nucleus. In addition to JAK/STAT and NF-B, the Ets gene family of transcriptional factors is also involved in the regulation of ICAM-1 expression (26, 27) . The control of highly diverse sets of genes by Ets proteins involves their own regulation at different levels which include, among others, specific phosphorylation events mediated by the Ras-MAPK pathway in response to extracellular signals (28) .
In T cells, the expression of many genes is tightly regulated by an equilibrium between two sets of enzymes with distinct properties, the protein-tyrosine kinases and protein tyrosine phosphatases (PTP). The role of protein-tyrosine kinases in T cell gene expression has been well documented (29) . Recently, some reports have described the role of PTP in T cell signaling and T cell transduction (30 -35) , but the involvement of PTP in the regulation of ICAM-1 gene expression in T cells is unclear. Of interest is the observation that the PTP inhibitor pervanadate can mimic IFN-␥-mediated induction of ICAM-1 expression via nuclear translocation of STAT-1 proteins in human keratinocytes (17) . Moreover, calyculin A and okadaic acid, two phosphoseryl/threonyl phosphatase inhibitors, induce an ICAM-1/LFA-1-dependant homotypic aggregation of both Jurkat and U937 cells (36) . However, the mechanisms leading to this ICAM-1/LFA-1 aggregation have not been defined. Altogether, these reports suggest that both PTP and phosphoseryl/ threonyl phosphatases are involved in ICAM-1 expression.
The primary objective of the present work was to investigate the role of PTP in the regulation of ICAM-1 gene expression in human T cells. We show here that treatment of primary human peripheral blood mononuclear cells and the human leukemic T cell lines Jurkat, HUT 78, and WE17/10 with the bis-peroxovanadium compound bpV[pic], a strong inhibitor of PTP, results in the induction of ICAM-1 surface expression. Further experiments revealed that NF-B, Ets, and pI␥RE-binding sites are important sequence motifs in bpV[pic]-mediated up-regulation of ICAM-1 expression. These results suggest that ICAM-1 is regulated in human T cells by PTP activity.
EXPERIMENTAL PROCEDURES
Reagents-Phorbol 12-myristate 13-acetate (PMA) and ionomycin (Iono) were purchased from Sigma and Calbiochem, respectively. Sodium orthovanadate (Sigma) was freshly dissolved before its use in 10 mM HEPES, pH 7.4. The bpV[pic] compound was prepared as described previously (37) . Briefly, V 2 O 5 was dissolved in an aqueous KOH solution and then mixed with 30% H 2 O 2 and an ancillary ligand (picolinic acid anion in this study hence bpV[pic]) in addition to the ethanol for optimal precipitation. Characterization of bpV[pic] was carried out by infrared 1 (40) . Flow Cytometry-Cell surface expression of ICAM-1 was evaluated by flow cytometry as follows. Jurkat, HUT 78, WE17/10 cells, and PBMCs (1 ϫ 10 6 ) were washed once in phosphate-buffered saline containing 2% FBS (PBSA). Cells were then resuspended in 100 l of PBSA to which was added 1 g of monoclonal anti-ICAM-1 antibody (clone RR1/1.1.1), vortexed gently, and incubated for 30 min on ice. Cells were subsequently washed with PBS containing 2% FBS and resuspended in 100 l of PBS containing (R)-phycoerythrin-conjugated goat anti-mouse IgG (0.5 g total) and further incubated for 30 min on ice. Cells were finally centrifuged and resuspended in 1% paraformaldehyde in PBS before being analyzed by flow cytometry (EPICS XL, Coulter Corp., Miami, FL).
Plasmids and Antibodies-Reporter plasmids of the ICAM-1 5Ј-regulatory element and mutants used in these experiments are cloned upstream from the firefly luciferase gene. pGL1.3, pGL1.3 Bmut, pGL HindIII, and pGL HindIII IRE mut were provided by Dr. T. P. Parks (Boehringer Ingelheim, Ridgefiel, CN), and pGLE WT, pGLE Ϫ138mut, pGLE Ϫ158mut, and pGLE Ϫ138/Ϫ158mut were kindly supplied by Dr. Y. de Launoit (Institut Pasteur, Lille, France). Anti-STAT-1, anti-STAT-3, and anti-p50 antibodies were purchased from Santa Cruz Biotechnology. Dr. N. Rice (NCI, Frederick, MD) kindly provided the polyclonal anti-p65 antibodies. Dr. Rothlein (Boehringer Ingelheim, Ridgefield, CN) provided the anti-ICAM-1 antibody RR1/1.1.1 (anti-CD54) (41) . The dominant negative IB␣-expressing vector pCMV-IB␣ S32A/36A has been described previously (42) (a kind gift from Dr. W. C. Greene, The Gladstone Institutes, San Francisco). The DNA filler pCMV-EcoRV/SmaI was constructed from the expressing vector pCMV-IB␣ S32A/36A by deletion of the cDNA encoding for IB␣ S32A/36A with EcoRV/SmaI digestion.
Transient Transfection by DEAE-Dextran-Jurkat cells (5 ϫ 10 6 ) were first washed once in TS buffer (137 mM NaCl, 25 mM Tris-HCl, pH 7.4, 5 mM KCl, 0.6 mM NaHPO 4 , 0.5 mM MgCl 2 , and 0.7 mM CaCl 2 ) and resuspended in 0.5 ml of TS containing 15 g of the indicated plasmids and 500 g/ml DEAE-dextran (final concentration). The cell/TS/plasmid/DEAE-dextran mixture was incubated for 25 min at room temperature. Thereafter, cells were diluted at a concentration of 1 ϫ 10 6 per ml using complete culture medium supplemented with 100 M chloroquine (Sigma). After 45 min of incubation at 37°C, cells were centrifuged, washed once, resuspended in complete culture medium, and incubated at 37°C for 24 h. Transiently transfected cells were seeded at a density of 10 5 cells per well (100 l) in 96-well flat-bottom plates. In most experiments, cells were left untreated or were either treated with bpV[pic], sodium orthovanadate, or PMA/Iono in a final volume of 200 l for a period of 8 h for bpV[pic] or 24 h for PMA/Iono and sodium orthovanadate. Cells were then lysed, and luciferase activity was monitored with a microplate luminometer (MLX; Dynex Technologies, Chantilly, VA).
Preparation of Nuclear Extracts-Jurkat cells were either left untreated or were incubated for different times at 37°C with bpV[pic] (10 M) or PMA/Iono (20 ng/ml and 1 M, respectively). Incubation of Jurkat cells with the various stimulating agents was terminated by the addition of ice-cold PBS, and nuclear extracts were prepared according to the microscale preparation protocol (43) . In brief, sedimented cells were resuspended in 400 l of cold buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride). After 15 min on ice, 25 l of 10% Nonidet P-40 was added. The lysate was vortexed for 10 s, and samples were centrifuged for 30 s at 12,000 ϫ g. The supernatant fraction was discarded, and the cell pellet was resuspended in 100 l of cold buffer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride). Cells were then rocked vigorously at 4°C for 15 min. Cellular debris were removed by centrifugation at 12,000 ϫ g for 5 min at 4°C, and the supernatant fraction was stored at Ϫ70°C until used.
Electrophoretic Mobility Shift Assay-Electrophoretic mobility shift assay was performed with 10 g of nuclear extracts. Protein concentrations were determined by the bicinchoninic assay with a commercial protein assay reagent (Pierce). Nuclear extracts were incubated for 30 min at room temperature in 15 l of buffer C (100 mM HEPES, pH 7.9, 40% glycerol, 10% Ficoll, 250 mM KCl, 10 mM dithiothreitol, 5 mM EDTA, 250 mM NaCl, 2 g of poly(dI-dC), 10 g of nuclease-free bovine serum albumin (fraction V) containing 0.8 ng of radiolabeled-labeled double-stranded DNA (dsDNA) oligonucleotide. Double-stranded DNA (100 ng) was labeled with [␥-32 P]ATP and T4 polynucleotide kinase in a kinase buffer (New England Biolabs, Beverly, MA). This mixture was incubated for 20 min at room temperature, and the reaction was stopped with 5 l of 0.2 M EDTA. The labeled oligonucleotide was extracted with phenol/chloroform and passed through a G-50 spin column. The dsDNA oligonucleotides, which were used as probes or as competitors, contained either the nonspecific probe Oct-2A (5Ј-GGAGTATCCAGCTCCGTAGCATGCAAA-TCCTCTGG-3Ј), the proximal NF-B-binding site (5Ј-GATTGCTTTAGC-TTGGAAATTCCGGAGCTG-3Ј), the distal NF-B-binding site (5Ј-AGG-GAGCCCGGGGAGGATTCCTGGGCC-3Ј), the pI␥RE (5Ј-AAGGCGGAG-GTTTCCGGGAAAGCAGCACC-3Ј), the wild-type Ϫ138/Ϫ158 Ets-binding sites (5Ј-CTGTCAGTCCGGAAATAACTGCAGCATTTGTTCCGGAG-GGGAAG-3Ј), or the Ϫ138/Ϫ158-mutated Ets-binding sites (5Ј-CTGTCA-GTCCCCAAATAACTGCAGCATTTGTTGGGGAGGGGAAG-3Ј) of the ICAM-1 5Ј-regulatory element. DNA-probe complexes were resolved from free labeled DNA by electrophoresis in native 4% (w/v) polyacrylamide gels containing 50 mM Tris-HCl, pH 8.5, 200 mM glycine, and 1 mM EDTA. The gels were subsequently dried and autoradiographed. Cold competitor assays were carried out by adding a 100-fold molar excess of homologous unlabeled dsDNA proximal or distal NF-B, pI␥RE, or Ets oligonucleo-tides simultaneously with the labeled probe. Supershift assays were performed by preincubation of nuclear extracts with 1 l of specific antibodies in the presence of all the components of the binding reaction described above for 30 min at 4°C.
RESULTS

ICAM-1 Expression Is Increased in Human T Lymphoid Cells and Primary Cells by the PTP Inhibitor bpV[pic]
-Given that intracellular tyrosine phosphorylation levels are crucial in the regulation of numerous genes, we investigated the effect of the PTP-specific inhibitor bpV[pic] on ICAM-1 protein expression in the human leukemic T cell line Jurkat and also in primary cells (i.e. PBMCs). In this set of experiments, cells were treated either with the PMA/Iono combination (as a control) or bpV[pic] compound, and the percentage of ICAM-1-expressing cells as well as the mean fluorescence intensity (indicative of the number of molecules per single cell shown on a logarithmic scale) were defined by flow cytometry analyses with the use of an antibody specific for ICAM-1 (clone RR1/1.1.1). As depicted in boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assays (data not shown). These data represent the first demonstration that PTPs are implicated in ICAM-1 gene expression in human T cells. It should be noted that we have made similar observations using HUT 78, another human T cell lymphoma line, and WE17/10, an IL-2-dependent T cell receptor/CD4-expressing cell line established from the blood cells of a patient with T cell lymphoma (Fig. 1, B and C, respectively). This last series of experiments indicate that the noticed bpV[pic]-mediated induction of ICAM-1 gene expression is not an epiphenomenon since it is observed in several human T cell lines.
Transcriptional Regulation of the ICAM-1 Gene by bpV[pic]
Compound-It is well documented that ICAM-1 gene expression is primarily regulated at the transcriptional level. In an attempt to study the effect of bpV[pic] on ICAM-1 transcription, a dose-response experiment was initially carried out using increasing concentrations of this PTP inhibitor. To this end, Jurkat cells were transiently transfected with a reporter construct made of the luciferase gene placed downstream of the entire ICAM-1 promoter (i.e. pGL1.3). Next, cells harboring the ICAM-1-luciferase vector were either left untreated or were treated for 8 h with the indicated bpV[pic] concentrations ( Fig.  2A) . A dose-dependent increase of ICAM-1 promoter activity in Jurkat cells transiently transfected with pGL1.3 was observed when using concentrations of bpV[pic] ranging from 1 to 10 M (1.2-42.9-fold increase). A slight decrease of ICAM-1-driven luciferase activity was detected at the highest concentration tested (i.e. 20 M) (34.0-fold increase), which could be due to cell toxicity. Subsequent experiments were thus conducted using bpV[pic] at a maximal concentration of 10 M. Sodium orthovanadate (Na 3 VO 4 ), a commonly used PTP inhibitor, was similarly tested in this series of investigations. As shown in Fig. 2B , a weak increase in ICAM-1-driven luciferase activity was obtained with concentrations of Na 3 VO 4 ranging from 12.5 to 50 M (1.1-1.5-fold induction). Therefore, these data suggest that bpV[pic] is a much more potent activator of ICAM-1 promoter transcription than the other PTP inhibitor tested, i.e. sodium orthovanadate. Kinetic analyses were also performed to define the appropriate incubation time to reach optimal bpV[pic]-and PMA/Iono-mediated activation of ICAM-1 transcription. As shown in Fig. 2C, bpV [pic] was found to be markedly more potent than PMA/Iono combination with respect to activation of ICAM-1 transcription. Moreover, maximal activation of ICAM-1-dependent luciferase activity was reached after 8 h following bpV[pic] treatment (22.6-fold increase), whereas the highest induction of ICAM-1 transcription was seen following 24 h of treatment with PMA/Iono (6.7-fold increase). These time points were thus used for the following series of investigations.
Identification of bpV[pic]-responsive Elements in the ICAM-1 Promoter in Human T Cells-By having demonstrated that bpV[pic] compound acts as a potent inducer of ICAM-1 transcription in human T cells, we next characterized the cisregulatory element(s) located within the 5Ј-flanking sequences of the ICAM-1 promoter that confers responsiveness to this tyrosine phosphatase-specific inhibitor. This goal was achieved using a series of ICAM-1 reporter constructs carrying either deletions or point mutations in the 5Ј region of the promoter and trans-dominant negative mutants of some specific transcription factors. Each of these molecular constructs was transiently transfected into Jurkat cells, and the luciferase activities of control, PMA/Iono, and bpV[pic]-treated cells were determined.
We initially tested the involvement of the mammalian ubiquitous transcription factor NF-B in bpV-induced activation of ICAM-1 promoter transcription. NF-B is a pleiotropic transcription factor complex that mediates the regulated expression of multiple immunomodulatory genes bearing cis-acting B enhancer elements, including the light chain of immunoglobulins, cytokines, as well as known genes for some cell adhesion molecules including ICAM-1 (44) . NF-B has been postulated to play a key role in the cell type-and stimulusspecific regulation of ICAM-1 (7) . Considering that the proxi- can be concluded that the proximal NF-B-binding site is a critical DNA-regulatory element responsible for ICAM-1 induction in T cells which is seen upon treatment with the PTPspecific inhibitor bpV [pic] .
Previous observations suggest that NF-B complexes can interact with other transcription factors that are recognized to bind to the ICAM-1 promoter (47, 48) . Thus, to address more completely the relative contribution of NF-B in bpV-dependent activation of ICAM-1 transcription, Jurkat cells were cotransfected with pGL1.3 and a construct encoding for a dominant negative version of IB␣ mutated to alanine on both serine 32 and 36 residues (i.e. pCMV-IB␣ S32A/36A). The IB␣ repressor protein encoded by pCMV-IB␣ S32A/36A is sequestered in the cytoplasm and renders the NF-B complex unable to translocate to the nucleus. The capacity of the used IB␣ repressor to abolish nuclear translocation and activation of NF-B was initially tested by transient transfection of Jurkat cells with pCMV-IB␣ S32A/36A and pNF-B-LUC, a vector made of five consensus binding sites for NF-B (data not shown). Transfection of the empty promoter vector (i.e. pCMV-EcoRV/SmaI) had no effect on bpV[pic]-mediated reporter gene activity (Fig. 3B ). However, when the mutated version of the repressor was instead used, incubation of the cells with bpV[pic] compound showed a marked reduction in ICAM-1 promoter activity (compare 35.0-and 16.0-fold increase). A more dramatic diminution of ICAM-1-driven reporter gene activity was seen following treatment with PMA/Iono combination (compare 7.8-and 1.0-fold induction). These data further confirmed the essential role played by NF-B in bpV[pic]-induced ICAM-1 promoter activity.
The ICAM-1 promoter contains also a more distal consensus NF-B-binding site. In an attempt to assess the putative implication of both domains in the noticed up-regulation of ICAM-1 transcription by bpV[pic] compound, the proximal and distal NF-B-binding sites of the ICAM-1 promoter were labeled and used as probes for DNA mobility shift assays. Nuclear extracts from untreated, PMA/Iono-, and bpV[pic]-treated Jurkat cells were used in these experiments. Nuclear proteins were extracted after 60 min of treatment with either PMA/Iono or bpV[pic] since maximal NF-B nuclear translocation was seen at this time (data not shown), an observation that is consistent with a previous report (49) . As illustrated in Fig. 4 , a complex was formed following treatment with both the tyrosine phosphatase-specific inhibitor bpV[pic] (Fig. 4A, compare  lanes 2 and 1) and PMA/Iono combination (Fig. 4B, compare  lanes 2 and 1) only when using the proximal NF-B-binding site as a probe. Indeed, no such complex could be induced by either PMA/Iono or bpV[pic] treatment when the distal NF-Bbinding site was used as a probe. The complex was competed away by the addition of a 100-fold molar excess of cold NF-B oligonucleotide (lanes 5). However, complex formation was not affected by a nonspecific oligonucleotide (Oct-2A) (lanes 6), demonstrating the specificity of the signal. To identify the NF-B proteins involved in complex formation, antibodies against two of the most prominent NF-B isoforms (i.e. p50 and p65) were incubated with nuclear extracts from PMA/Iono-and bpV[pic]-treated Jurkat cells before the addition of labeled probes. Antibody against p50 significantly decreased the complex formation and a supershift (lanes 3), whereas anti-p65 antibody caused a partial supershift (lanes 4). It is thus clear that the protein complex bound to the proximal NF-B-binding site of the ICAM-1 promoter is composed of both p50 and p65 subunits. These results clearly indicate that bpV[pic] compound is mediating nuclear translocation of NF-B, and such a finding is perfectly in line with our previous transcriptional studies (Figs. 2 and 3) .
Our previous results indicated that a point mutation in the proximal NF-B-binding site or the use of a dominant negative form of the IB␣ repressor did not completely eliminate the ability of the full-length ICAM-1 promoter to respond to bpV[pic] (Fig. 3, A and B) . Thus, it suggests that NF-B-independent signal transduction pathway(s) might be involved as well. Previous studies have identified two functional Ets-binding sites in the ICAM-1 proximal promoter (26, 27) . It should be emphasized that the role of these two transcription regulatory elements in human T cells with respect to the transcriptional regulation of the ICAM-1 gene remains to be defined. Cells were then transfected in a transient fashion with a luciferaseencoding vector driven by the first 176 nucleotides of the ICAM-1 promoter region (pGLE WT). This region of the ICAM-1 promoter harbors two Ets-binding sites (positions Ϫ138 and Ϫ158 relative to the start of transcription) in addition to the pI␥RE, Sp1-and AP-2-binding sites, and a TATA box. Moreover, cells were also transfected with molecular constructs bearing point mutations either at each (pGLE Ϫ138mut and pGLE Ϫ158mut) or both (pGLE Ϫ138/Ϫ158mut) Ets-bind- tion was observed when using wild-type and mutated versions of the ICAM-1 promoter carrying single point mutation in either Ϫ138 or Ϫ158 Ets-binding site (Fig. 5 ). Interestingly, when both Ets-binding sites were mutated, the induction by bpV[pic] was severely reduced (31.2-fold versus 14.2-fold increase). It should be noted that PMA/Iono-mediated induction of ICAM-1 transcription is not markedly affected by such mutations. To determine whether these two sequence motifs can function as protein-binding sites, the responsive region composed of both Ϫ138 and Ϫ158 wild-type Ets-binding sites was labeled and used as a probe for mobility shift assays. First, we noticed that there was a constitutive nuclear translocation of Ets in Jurkat cells that was not modulated by a treatment with bpV[pic] or PMA/Iono (Fig. 6, compare lanes 1 and 2) . It has been previously demonstrated that IFN-␥ induces STAT-1, whereas IL-6 mediates binding of both STAT-1 and STAT-3 transcriptional factors to the pI␥RE element in the ICAM-1 promoter (17, 50) . Thus, we defined whether the bpV[pic]-induced complex is constituted of either STAT-1, STAT-3, or both by performing supershift analyses. To this end, nuclear proteins were extracted from untreated and bpV[pic]-treated Jurkat cells (60 and 120 min) before incubation with anti-STAT-1 or anti-STAT-3 antibody and the radiolabeled ICAM-1 pI␥RE. Antibody against STAT-1 diminished the binding and caused a partial supershift of the bpV[pic]induced complex (compare lane 4 and 3) , whereas anti-STAT-3 antibody did not affect the complex formation mediated by bpV[pic] treatment (compare lanes 5 and 3) . These results suggest that bpV[pic] results in the formation of a DNA-protein complex constituted of ICAM-1 pI␥RE site and STAT-1 transcription factor. 1 and 7) or treated for 60 min with bpV[pic] (A, lanes 2-6 and 8 -12) or PMA /Iono combination (B, lanes 2-6 and 8 -12 ). Binding specificity was tested by adding a 100-fold molar excess of either cognate NF-B oligonucleotide (lanes 5 and 11) or a nonspecific (non-spec) probe (Oct-2A) (lanes 6 and 12) . For gel supershift assays, nuclear extracts were also incubated with antibody against p50 and p65 isoforms. These results are representative of three independent experiments.
DISCUSSION
ICAM-1 gene expression is regulated by numerous inducing (e.g. TNF-␣, IFN-␥, PMA, and IL-1) or inhibitory factors (e.g. IL-4, IL-10, and glucocorticoids). The architecture of the ICAM-1 promoter is complex and is thus regulated by an interplay between different transcription factors such as STAT, NF-B, Ets, C/EBP, and Sp1 as demonstrated in various cell types including acute myeloid leukemia blast cells, B lymphocytes, endothelial cells, and epithelial cells (7, 8) . Previous studies reported that protein phosphorylation could be involved in ICAM-1 gene expression. In human monocytic U937 and human lymphocytic Jurkat cell lines, okadaic acid and calyculin A (Ser/Thr phosphatases inhibitors) promote ICAM-1 and LFA-1-mediated homotypic aggregation (36) . In addition, phenylarsine oxide, pervanadate, and diamide (PTP inhibitors) have been shown to block the TNF-induced endothelial cell surface adhesion molecules (ICAM-1, VCAM-1, and ECAM-1) (45) . Another study reported that pervanadate mimics the IFN-␥ induction of ICAM-1 gene expression (17) . Although central to many different pathways in T cells, tyrosine phosphorylation events per se have not been directly investigated in the regulation of ICAM-1 gene expression. In this study, we have thus analyzed the role of tyrosine phosphorylation events in transcriptional regulation of the ICAM-1 promoter in human T cells. The bpV[pic] compound, previously characterized as one of the most potent PTP inhibitors, was used in this study to break the equilibrium between PTP and protein-tyrosine kinases and therefore to increase intracellular phosphotyrosine levels.
Our results first demonstrated that bpV[pic] was effective in inducing ICAM-1 surface expression. Flow cytometry analyses showed that bpV[pic] compound was able to increase both the number of ICAM-1-expressing cells and the mean fluorescence intensity. The physiological significance of the current work was provided by the observation that bpV[pic] treatment leads to the induction of ICAM-1 expression not only in established T cell lines (i.e. Jurkat, HUT 78, and WE17/10) but also in primary human PBMCs. Further experiments revealed that the up-regulatory effects of bpV[pic] on ICAM-1 transcriptional activity are far superior than those of sodium orthovanadate (Na 3 VO 4 ), another described powerful PTP inhibitor. Interestingly, such results are consistent with a previous report showing that bpV molecules are more potent inducers of human immunodeficiency virus promoter activity than Na 3 VO 4 (49) . These observations suggest that the inhibitory effects of bpV[pic] on intracellular PTP may be distinct from those of sodium orthovanadate, in terms of potency and/or substrate specificity. Further studies are needed to shed light on this matter.
Data from several reports have clearly indicated that the transcription factor NF-B is playing a central role in the induction of ICAM-1 (25, 46 -48) that is seen following treatment with PMA, TNF-␣, IL-1, and lipopolysaccharide (20, 24, 51) . This family of transcriptional factors has the ability to interact with other transcriptional factors such as Fos/Jun, C/EBP, and Sp1 (52) (53) (54) . Our results are perfectly in line with these previous observations since we defined that NF-B is a second messenger actively participating in bpV[pic]-mediated expression of ICAM-1 in human T cells. Although Imbert and colleagues (55) 6) . Binding specificity was tested by adding a 100-fold molar excess of a probe constituted of either the cognate Ϫ138/Ϫ158 WT Ets oligonucleotide (lanes 3 and 7) or a nonspecific (non-spec) probe (Oct-2A) (lanes 4 and 8) . These results are representative of three independent experiments. phosphorylation on both serine residues 32 and 36 of IB␣. This series of events is known to be necessary to ensure dissociation of IB␣ from NF-B through ubiquitination of IB␣ and its final degradation by the proteasome. Our data indicate also that bpV[pic]-mediated activation of ICAM-1 gene expression is dependent on both p50 and p65 NF-B/Rel family members. These findings are consistent with previous reports indicating that the ICAM-1 B site binds p50 and p65 (20, 48) . Although we provide conclusive evidence of the intimate interplay between the phosphotyrosine level and NF-B-dependent induction of ICAM-1 expression in T cells, the various putative protein-protein interactions between NF-B complexes and other transcription factors binding to the ICAM-1 promoter (e.g. AP-1 and C/EBP) remain to be explored.
The nuclear phosphoproteins Ets have been reported to be involved in activation of the ICAM-1 promoter in various cell types including rabbit kidney carcinoma, human choriocarci-noma, and endothelial cell lines (26, 27) . To evaluate the implication of Ets transcriptional factors in bpV-mediated activation of ICAM-1, we transiently transfected Jurkat cells either with pGLE, pGLE Ϫ138mut, pGLE Ϫ158mut, or pGLE Ϫ138/ Ϫ158mut. Our results demonstrated that no significant change occurred following a point mutation in either the Ϫ138 (pGLE Ϫ138mut) or Ϫ158 (pGLE Ϫ158mut) Ets-binding sites when compared with a vector carrying the wild-type Ets-binding sites (pGLE WT). However, when both Ets-binding sites were mutated, the bpV[pic]-induced up-regulation of ICAM-1 promoter-driven luciferase activity was significantly decreased. Our results are contrasting with previous data indicating that a point mutation in the Ϫ158 Ets-binding site strongly diminished the ICAM-1 promoter activity (27) . In this report, it was demonstrated that expression vectors encoding for Ets-2 and ERM significantly up-regulate ICAM-1 transcription in rabbit kidney carcinoma RK13 cells, and the ERM-mediated activation of ICAM-1 transcription was strongly diminished when using a mutated Ϫ158 Ets-binding site. In addition, a mutated version of the Ϫ138 Ets-binding site did not change the ERMmediated induction of ICAM-1 gene expression. There are at least two possibilities that could explain such a discrepancy. First, experiments conducted by de Launoit and co-workers (27) were performed using established cell lines different from the one used in the current study. Second, in contrast to their work that is based on overexpression of Ets-2 and ERM, we could not detect any positive modulation of Ets nuclear translocation upon bpV[pic] treatment. The observation that both Ets-binding sites in the ICAM-1 promoter are important for bpV[pic]-mediated induction of ICAM-1 transcription despite an absence of Ets activation is suggestive of a functional interaction between binding sites for Ets and another transcription factor. This possibility is supported by a previous study demonstrating that the H 2 O 2 -responsive element in the ICAM-1 promoter is constituted of the Ets-and AP-1-binding sites (26) . Similarly, a synergic activation of ICAM-1 by retinoic acid and TNF-␣ is due to a functional cooperation between retinoic acid response elements and NF-B-binding sites (56) . Further studies are warranted to identify the binding site(s) in the ICAM-1 promoter that functionally cooperate with Ets-binding sites to form the bpV[pic]-responsive elements.
In addition to binding sites for NF-B and Ets transcription factors, our results indicate that the JAK/STAT signaling pathway is also implicated in the induction of ICAM-1 expression in human T cells that is seen upon treatment with the potent PTP inhibitor bpV compound. Indeed, a point mutation in the IFN-␥-responsive element (i.e. pI␥RE) markedly reduced bpV[pic]mediated up-regulation of ICAM-1 promoter activity. We also demonstrated that bpV[pic] treatment was resulting in nuclear translocation of STAT-1. Our results are consistent with a 10) . Binding specificity was tested by adding a 100-fold molar excess of a probe composed of either the cognate pI␥RE oligonucleotide (lanes 6 and 13) or a nonspecific (non-spec) probe (Oct-2A) (lanes 7 and 14) . For gel supershift assays, nuclear extracts were also incubated with antibody specific either for STAT-1 (lanes 4 and 11) or STAT-3 (lanes 5 and 12) . These results are representative of three independent experiments. previous report demonstrating that the PTP inhibitor pervanadate activates the protein-tyrosine kinases JAKs which will in turn induce tyrosine phosphorylation of STAT-1, STAT-3, and STAT-6 (57) . Of interest for the present study, STAT-1 has been recently shown to be inactivated by a nuclear PTP (58) . Therefore, it can be proposed that the PTP inhibitor bpV [pic] could result in phosphorylation of STAT-1 in the cytoplasm, translocation to the nucleus, and then the maintenance for a longer period of a high level of STAT-1 in an active phosphorylated state.
In conclusion, our findings indicate that ICAM-1 gene expression in human T cells is under the control of constitutive PTP activity, which serves to maintain ICAM-1 expression at a basal level. A more detailed understanding of the transcription factors involved in bpV[pic]-mediated activation of ICAM-1 expression will be needed to determine how the various cooperative protein-protein interactions regulate the transcriptional activation of the ICAM-1 gene in human T cells.
